Literature DB >> 23604380

IL-17 in lung disease: friend or foe?

Hui-Leng Tan1, Mark Rosenthal.   

Abstract

Interleukin 17 (IL-17) is a key proinflammatory cytokine in the T helper 17 pathway. While it is important in the clearance of certain pathogens, IL-17 has been shown to contribute to the pathogenesis of such inflammatory diseases as rheumatoid arthritis and psoriasis. In the lung, it has been postulated to be involved in the neutrophilic inflammation and airway remodelling of chronic respiratory conditions but the situation is increasingly complex. This review summarises the evidence for its role in several chronic inflammatory lung diseases: asthma, obliterative bronchiolitis, chronic obstructive pulmonary disease, sarcoidosis and cystic fibrosis.

Entities:  

Keywords:  Asthma; Cystic Fibrosis; Cytokine Biology; Respiratory Infection

Mesh:

Substances:

Year:  2013        PMID: 23604380     DOI: 10.1136/thoraxjnl-2013-203307

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  33 in total

1.  Neuroimmune semaphorin 4A as a drug and drug target for asthma.

Authors:  G Mogie; K Shanks; E H Nkyimbeng-Takwi; E Smith; E Davila; M M Lipsky; L J DeTolla; A D Keegan; S P Chapoval
Journal:  Int Immunopharmacol       Date:  2013-08-28       Impact factor: 4.932

2.  Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation.

Authors:  Daniel Hsu; Patricia Taylor; Dave Fletcher; Rolf van Heeckeren; Jean Eastman; Anna van Heeckeren; Pamela Davis; James F Chmiel; Eric Pearlman; Tracey L Bonfield
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

3.  Dynamic variations of the peripheral blood immune cell subpopulation in patients with critical H7N9 swine-origin influenza A virus infection: A retrospective small-scale study.

Authors:  Cheng Chen; Wei Sun; Jun Chen; Jian-An Huang
Journal:  Exp Ther Med       Date:  2017-02-21       Impact factor: 2.447

Review 4.  Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases.

Authors:  Maaike Cockx; Mieke Gouwy; Jo Van Damme; Sofie Struyf
Journal:  Cell Mol Immunol       Date:  2017-11-27       Impact factor: 11.530

Review 5.  Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.

Authors:  Laurent Meijer; Deborah J Nelson; Vladimir Riazanski; Aida G Gabdoulkhakova; Geneviève Hery-Arnaud; Rozenn Le Berre; Nadège Loaëc; Nassima Oumata; Hervé Galons; Emmanuel Nowak; Laetitia Gueganton; Guillaume Dorothée; Michaela Prochazkova; Bradford Hall; Ashok B Kulkarni; Robert D Gray; Adriano G Rossi; Véronique Witko-Sarsat; Caroline Norez; Frédéric Becq; Denis Ravel; Dominique Mottier; Gilles Rault
Journal:  J Innate Immun       Date:  2016-03-18       Impact factor: 7.349

Review 6.  Defining COPD-Related Comorbidities, 2004-2014.

Authors:  Carlos H Martinez; David M Mannino; Miguel J Divo
Journal:  Chronic Obstr Pulm Dis       Date:  2014-05-06

Review 7.  Innate Immunity of the Lung: From Basic Mechanisms to Translational Medicine.

Authors:  Dominik Hartl; Rabindra Tirouvanziam; Julie Laval; Catherine M Greene; David Habiel; Lokesh Sharma; Ali Önder Yildirim; Charles S Dela Cruz; Cory M Hogaboam
Journal:  J Innate Immun       Date:  2018-02-13       Impact factor: 7.349

Review 8.  Aligning mouse models of asthma to human endotypes of disease.

Authors:  Rebecca A Martin; Samantha R Hodgkins; Anne E Dixon; Matthew E Poynter
Journal:  Respirology       Date:  2014-05-09       Impact factor: 6.424

Review 9.  Key mediators in the immunopathogenesis of allergic asthma.

Authors:  Sannette Hall; Devendra K Agrawal
Journal:  Int Immunopharmacol       Date:  2014-06-13       Impact factor: 4.932

10.  Robust Cytokine and Chemokine Response in Nasopharyngeal Secretions: Association With Decreased Severity in Children With Physician Diagnosed Bronchiolitis.

Authors:  Erin G Nicholson; Chelsea Schlegel; Roberto P Garofalo; Reena Mehta; Margaret Scheffler; Minghua Mei; Pedro A Piedra
Journal:  J Infect Dis       Date:  2016-05-18       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.